Worst Pills - generic-tadalafil.info
rosuvastatin (CRESTOR)

Drug and Dietary Supplement Profiles

A comprehensive review of the safety and effectiveness of this drug. If the drug is not a Do Not Use product, information on adverse effects, drug interactions and how to use the medication are included.
Search results below include drug profiles where your selected drug is a primary subject of discussion
  • rosuvastatin (CRESTOR)
    We list this drug as a Do Not Use drug because it causes kidney, muscle and liver damage.

Disease and Drug Family Information

Search results below include Disease and Drug Family Information where your selected drug is a primary subject of discussion
  • Elevated Cholesterol Levels [hide all summaries]
    The evidence for treatment, especially with cholesterol-lowering drugs, is much weaker for people who have not yet had the cardiovascular disease described above, known as primary prevention. This is especially so for those people who do not have more than one of the following risk factors: hypertension, diabetes, smoking, obesity, or a close family history of premature heart attacks or strokes.

Worst Pills, Best Pills Newsletter Articles

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a primary subject of discussion

Additional Information from Public Citizen

Search results below include Additional Information from Public Citizen where your selected drug is a primary subject of discussion
  • [hide all summaries]
    Letter to the editor that appeared in the April 2005 issue of Pharmacoepidemiology and Drug Safety. Submitted by Amer Ardati MD, Paul Stolley MD, Deanne E. Knapp PhD, Sidney M. Wolfe MD and Peter Lurie MD, MPH*
  • [hide all summaries]
    Statement of Sidney Wolfe, M.D. regarding the FDA's decision to leave Crestor on the market (HRG Publication #1730)
  • [hide all summaries]
    Crestor (rosuvastatin) has 2.8 times the rate of rhabdomyolysis of the second most toxic statin, analysis shows
  • [hide all summaries]
    Letter to FDA urging action on misleading CRESTOR advertising by AstraZeneca (HRG Publication #1712)
  • [hide all summaries]
    Letter to FDA Renewing Call for Crestor to Be Removed From Market. Rate of Kidney Damage in Crestor Patients Is 75 Times Higher Than in Patients Taking Other Cholesterol Drugs (HRG Publication #1710)
  • [hide all summaries]
    The lipid-lowering drug rosuvastatin is currently in the midst of the most heavily financed launch of a prescription drug ever. Here I present premarketing and postmarketing evidence of the dangers of the drug, and call for its removal from the market. Detailed briefing documents including unpublished reviews of safety and efficacy data from clinical trials are now made public on the internet before all Food and Drug Administration (FDA) advisory committee meetings discussing the approval of a new drug.
  • [hide all summaries]
    Public Citizen Calls for Criminal Investigation of AstraZeneca. Company Illegally Delayed Submitting Reports of Serious Adverse Reactions to Cholesterol Drug Crestor.
  • [hide all summaries]
    Letter to NIH Director questioning the propriety of the actions of a senior NIH scientist who was a consultant for AstraZeneca. was the editor of the proceedings of a symposium and the author of an article in the proceedings containing an incomplete, inaccurate analysis understating the serious risks of AstraZeneca’s cholesterol-lowering drug, rosuvastatin (Crestor).
  • [hide all summaries]
    As you are aware, on March 4th of this year, we petitioned the FDA to ban the recently-marketed cholesterol-lowering drug rosuvastatin (Crestor/AstraZeneca) because of seven post-marketing cases of life-threatening rhabdomyolysis and nine cases of renal failure or renal insufficiency,
  • [hide all summaries]
    We have obtained new information from the FDA and health agencies in Canada and the U.K. concerning serious post-marketing adverse reactions – including seven cases of life-threatening rhabdomyolysis (muscle destruction) and nine cases of kidney failure or kidney damage – in patients mostly using lower doses of this recently-approved cholesterol-lowering drug, rosuvastatin.
  • [hide all summaries]
    In summary, we strongly oppose the approval of rosuvastatin because of its unique renal toxicity. We are also seriously concerned because of the seven cases of rhabodmyolysis that were common enough to have shown up in clinical trials, unlike the pre-approval studies with all previously approved statins, including cerivastatin.

SHOW secondary search results for rosuvastatin (CRESTOR)